Teresa Graham, CEO of Roche Pharmaceuticals said of the exclusive collaboration and licensing agreement, “We are excited to collaborate with Zealand Pharma and develop this promising therapy, which we hope will provide people living with obesity and related comorbidities a new treatment option,”

The Zealand Pharma deal highlights the growing investments in biotech obesity drugs as pharma giants speed up for developing new weight loss treatments. Under the deal, Zealand Pharma will get a payment of $1.65 billion. Other milestone payments summing up to $5.3 billion will be based on Phase 3 trial results and sales performance, Roche said.

The Roche Zealand Pharma Deal

The Roche Zealand Pharma agreement includes an upfront payment of $280 million for Zealand Pharma and with some further milestone payments worth potentially a total of $5.3 billion. The agreement gives Roche exclusive global rights for the development, manufacturing, and marketing of the obesity drug candidate.

In the United States and Europe, Zealand and Roche will together do the commercialization of Petrelintide.  While Roche will hold exclusive commercialization rights for the rest of the world. Profits and losses for Petrelintide, along with a fixed-dose of Roche’s CT-388, will be shared equally, according to Roche.

Competition Heats Up

The Zealand Pharma partnership puts Roche in competition with big pharmaceutical companies, such as Novo Nordisk and Eli Lilly. These drugs have changed the market. It enables patients to lose substantial amounts of weight and reduce the risk of obesity-related conditions. This deal is Roche’s bet that it can push a breakthrough therapy to market successfully, and it could gain an edge in competitiveness in the multi-billion-dollar-obesity-drug market.

As the global fight against obesity intensifies, Roche’s obesity drug collaboration with Zealand Pharma could mark the beginning of a new era in weight loss treatments. The success of this partnership will be closely watched as both companies work to bring a new, innovative therapy to patients worldwide.

The post Roche Secures Zealand Pharma’s Obesity Drug in $5.3 Billion Deal appeared first on Tech Research Online.

Bohumil was one of the top manufacturing facilities during the COVID-19 pandemic for Novavax that produced its protein-based COVID-19 vaccine, Nuvaxovid. However, with declining global vaccine demand, Novavax Czech Republic operations became less central to the company’s strategy.

Novavax Announces Sale

According to Novavax President and CEO John C. Jacobs, the decision to sell aligns with the company’s broader goals. “The decision to sell the Czech Republic manufacturing facility aligns with our previously announced commitment to evolve Novavax into a more lean and agile organization focused on partnering our pipeline assets and technology platform,” Jacobs stated.

The Novavax sale announcement reinforces the company’s commitment to advancing its pipeline, which includes vaccines targeting a standalone influenza vaccine and COVID-19 influenza combination vaccine.

Moreover, the company has been falling behind vaccine makers including Moderna and Pfizer, who achieved more than 3 billion in sales for their mRNA COVID-19 shots in the third quarter. The sale of Novavax’s Czech Republic manufacturing facility comes soon after the vaccine manufacturer signed a licensing deal, worth $1.2 billion deal with French drugmaker, Sanofi for a 5% stake in their business

Novo Nordisk Deal

The Novo Nordisk deal is remarkable for the Danish pharmaceutical company, which is already a world leader in treatments regarding diabetes and obesity care. The acquisition of the Bohumil facility will help Novo Nordisk increase its production of active pharmaceutical ingredients to meet the growing demand in the global market.

This acquisition of Novovax’s Czech manufacturing unit will be of strategic importance for Novo Nordisk as it will help in improving its global network of manufacturing and support in achieving long-term growth goals. The Bohumil site will also be important in accomplishing Novo Nordisk’s current aim of diversifying and growing its product range, especially in areas of high customer interest.

Novavax Czech Republic Sale

The $200 million transaction provides a financial boost to Novavax, to help the company overcome the decline in revenue from COVID-19 vaccines. For Novo Nordisk, adding the Bohumil site is a strategic move toward scaling its API production as it continues to be an innovation leader and market player.

This Novo Nordisk expansion represents a new dynamic in the pharmaceutical industry where companies prioritize asset optimization and strategic partnerships. The deal is expected to close in early 2025, depending on regulatory approvals and customary closing conditions.

The post Novavax Sale Czech Republic: $200 Million Novo Nordisk Deal Announced appeared first on Tech Research Online.

Stop the Revenue Drain: Conquer Claim Denials & Accelerate Payments

Simplify patient payments. Watch revenue soar.

Are you a healthcare provider drowning in a sea of claim denials, payment delays, and endless paperwork? Are you tired of watching your hard-earned revenue slip through the cracks due to a complex and inefficient billing process? It’s time to reclaim control, optimize your revenue cycle, and get paid faster. 

In This Free Webinar, You’ll Discover:

• The Challenges: Why claim denials, delays, and audits are so common in today’s healthcare landscape.
• The Solution: How technology can streamline your claims process, reduce errors, and accelerate payments.
• The Inovolon Advantage: Why our all-in-one platform is the key to simplifying your billing workflow and improving your bottom line.

Join Webinar

Join Webinar

[contact-form-7]

The post Stop the Revenue Drain: Conquer Claim Denials & Accelerate Payments appeared first on Tech Research Online.

Skilled Nursing Group Gets Paid Faster, Sees Fewer Denials with Inovalon

See how HMG Healthcare Improved Cash Flow and Efficiency  

Is slow reimbursement and high denial rates impacting your skilled nursing facility’s bottom line? HMG Healthcare faced similar challenges until they implemented Inovalon’s innovative software solutions. Learn how they transformed their revenue cycle management, improved cash flow, and enhanced patient satisfaction. 

In this case study you will learn how about:

• HMG Healthcare overcame the challenges of slow reimbursements and high denial rates.
• Inovalon’s software helped streamline the claims management process.
• The impact of faster claim processing on cash flow.
• How HMG Healthcare increased their clean claim rate and reduced denials.
• The role of technology in improving patient experience.

Download the case study

Download the case study

[contact-form-7]

The post Skilled Nursing Group Gets Paid Faster, Sees Fewer Denials with Inovalon appeared first on Tech Research Online.

Maintaining Your Practice Autonomy:

5 Ways to Increase Profitability and Reduce Your Administrative Burden 

The post Maintaining Your Practice Autonomy appeared first on Tech Research Online.

Nurture Patient Loyalty with Convenient Payments

Simplify patient payments. Watch revenue soar.

The post Nurture Patient Loyalty with Convenient Payments  appeared first on Tech Research Online.

Stored Card Technology Boosts Convenience and Reimbursements for Pediatrics Group

Discover how stored card technology revolutionized operations for a pediatrics group, enhancing convenience and streamlining reimbursements.

The post Stored Card Technology Boosts Convenience and Reimbursements for Pediatrics Group  appeared first on Tech Research Online.

GoJoe’s co-founder, Will Turner said, “ The investor not only allows GoJoe to increase its resources to support its growth, but also widen its reach in supporting businesses in the health and fitness challenges they face in the modern workplace.”

Tech.eu reported that the GoJoe health and fitness app has had a significant impact on users who were not as active previously.

Big Backing

GoJoe attracted support from big funders in the recent funding round. The funding round was led by Redrice Ventures and Venrex Partners, with the support of Amrock Ventures.

Venrex Partners Invest Alistair Russell said, “We’re thrilled to be involved with GoJoe at the intersection of the sports and consumer sectors. We’re particularly excited to leverage our experience from investors in other successful consumer and sports-related startups, such as Ellipse Data and Revolut. The team embodies many of the characteristics of the most successful founders we’ve partnered with at Venrex.”

GoJoe is supported by Superbet Ventures and a host of angel investors. The angel investors include footballer and coach Michael Carrick and Olympian Alistair Brownlee.

“It’s really exciting to welcome investment from leading firms who have helped scale some remarkable businesses and build household brands. In recent years, we’ve demonstrated the huge value that a social product like ours can have on individuals and companies they work for,” Turner added.

Gamification in Fitness

The GoJoe app leverages social accountability and gamification to motivate users to achieve higher mental, physical, and social health. It helps businesses to meet employee well-being needs. The app comes with a range of in-app features and functions that support virtual team-based challenges.

It includes live tracker maps and a weighted point system for each of its 50 activities. Users can train virtually alongside professional athletes and celebrities. Enterprise clients have reported that 61% of their employees have experienced significant health improvements in their social, mental, and physical spheres.

The impact is more pronounced in lightly active and sedentary users. In some instances, previously inactive users have reported up to 800% increase in activity.

Global Reach

The GoJoe gamification app is currently being used in over 150 countries. The app is designed to break location, physical, tech, and language barriers. This allows it to offer users global and inclusive benefits. Companies from any part of the world can access health insurance and GoJoe employee assistance programmes from a single location.

The health tech company is currently partnering with top health insurance companies to quantify the impact its product has on reducing health incidences, premiums, and claims.

The health tech startup is also integrating the GoJoe app with human resource management systems. This integration will help in quantifying the impact of low absenteeism resulting from physical and mental health.

The post GoJoe Raises $3.07M to Expand Health and Fitness App Reach appeared first on Tech Research Online.